TP53 and cancer: Next-generation sequencing analysis of 520 cancer-related genes revealed that eleven patients harboring mutations in the TP53 pathway exhibited significantly poorer prognoses compared to those with wild-type genes (n = 38), demonstrating a statistically significant difference in three-year overall survival (OS) (33.5% vs. 59.9%, p = 0.031) [50].